3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
72
Breast Neoplasms
9
Neoplasm Metastasis
8
Prostatic Neoplasms, Castration-Resistant
6
Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Prostate Cancer Metastatic
3
Metastatic Castration Resistant Prostate Cancer
3
Bulbo-Spinal Atrophy, X-Linked
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Metastatic Hormone Sensitive Prostate Cancer
2
Melanoma
2
mCRPC
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ureteral Diseases
1
Solid Tumours
1
Small Cell Lung Carcinoma
1
Seizures
1
Salivary Cancer
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Pancreatic Neoplasms
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Squamous Cell
1
Metastatic Progressive Castration-resistant Prostate Cancer
1
Interventions
Dexamethasone
43
Cyclophosphamide
38
fludarabine phosphate
27
Cytarabine
26
Rituximab
24
Methotrexate
21
Lenalidomide
21
Bortezomib
21
Calcium Dobesilate
20
fludarabine
19
Peripheral Blood Stem Cell Transplantation
19
Whole-Body Irradiation
16
Mycophenolic Acid
16
pembrolizumab
15
Gemcitabine
15
Etoposide
15
pomalidomide
14
Melphalan
14
Vincristine
13
Filgrastim
13
Busulfan
13
Tacrolimus
12
Cyclosporine
12
Carboplatin
12
Paclitaxel
11
carfilzomib
10
durvalumab
9
Doxorubicin
9
Cetuximab
9
Brentuximab Vedotin
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Recurrence
×
enzalutamide
×
Clear all
No trials found.